Objective:To investigate the application value of CD278 combined with programmed cell death protein-1 (PD-1) double positive expression in identifying neoplastic T cells in angioimmunoblastic T-cell lymphoma (AITL).Methods:A retrospective analysis was performed on bone marrow and/or peripheral blood samples from 52 pathologically confirmed AITL patients admitted to Jiangsu Provincial Hospital between January 11, 2024 and March 15, 2025. Among the patients, there were 40 males and 12 females, with a median age of 66 (61, 71) years old. Meanwhile, 40 healthy subjects receiving physical examination were enrolled as the control group, including 24 males and 16 females, with a median age of 59(47, 62) years. Multiparameter flow cytometry (FCM) was performed using a 9-color antibody panel comprising CD45, CD3, CD4, CD5, CD7, CD10, CD2, CD278, and PD-1. Combined with forward scatter (FSC) and side scatter (SSC), the immunophenotype of CD4+T cells was analyzed according to the gating strategy for target lymphocytes. The cut-off value of CD278+PD-1+ expression ≥20% was defined as positive criterion. Evaluating the efficacy of single and combined biomarkers in identifying tumor T cells using receiver operating characteristic (ROC) curves and area under the curve (AUC)
.Results:Abnormal immunophenotypic CD4+ T cells were detected in 73.1% (38/52 cases) of 52 AITL patients, among which 94.7% (36/38 cases) exhibited CD3 downregulation, with statistically significant difference compared with the control group (0/40 cases,
P<0.001). All 38 cases of abnormal CD4+ T cells expressed CD5 and CD45. Of these abnormal cells, 94.7% (36/38 cases) showed CD278 and PD-1 double positive expression, whereas no such population was identified in the control group (0/40 cases,
P<0.001). Using the detection of CD278+PD-1+ abnormal CD4+ T cells in bone marrow and/or peripheral blood as an indicator to identify neoplastic T cells, the sensitivity and specificity were 69.2% (36/52 cases) and 100% (40/40 cases), respectively. ROC curve analysis revealed that the area under curve (AUC) of combined CD278 and PD-1 detection was 0.974 (95%
CI 0.932-1.000,
P<0.001), which was significantly higher than single PD-1 detection (AUC=0.699, 95%
CI 0.581-0.816,
P=0.002).
Conclusion:CD278 and PD-1 double positive expression serves as an important immunophenotypic marker for identifying AITL neoplastic cells, which enables detection of AITL cells with low proportions in bone marrow and peripheral blood.